Ki-CONNECT Now

Ki-CONNECT has agreed and signed a contract with Thyas Co. Ltd. to provide academic support.

Ki-CONNECT has agreed and signed a contract with Thyas Co. Ltd. to provide academic support for the development of autologous immuno-oncotherapy using iPS cell-derived Killer T-cells.

Thyas Co., Ltd. is a startup Biotech company, developing cancer immunotherapy using rejuvenated iPSC-derived T cells (iPS-T) for the treatment of solid tumors. Its technologies are based on iPSC-to-T-cell differentiation methods established by Dr. Shin Kaneko, the Center for iPS cell Research and Application, Kyoto University, Kyoto, Japan.